Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Anavex Life Sciences Corp AVXL

Healthcare Biotechnology
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of... see more

Recent & Breaking News (NDAQ:AVXL)

Mid-Morning Market Update: Markets Open Higher; BlackBerry Earnings Beat Estimates

Benzinga.com  September 28, 2016

18 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  September 28, 2016

Anavex Compound to be Tested in Biogen Neurological Protection Model

GlobeNewswire September 28, 2016

15 Biggest Mid-Day Gainers For Thursday

Benzinga.com  September 22, 2016

Anavex Life Sciences’ Drug Shows Efficacy to Support Potential Disease Modification in Parkinson’s Disease

GlobeNewswire September 22, 2016

Anavex to Present at Ladenburg Thalmann 2016 Healthcare Conference

GlobeNewswire September 20, 2016

Anavex to Participate in Mizuho Therapeutics Conference

GlobeNewswire September 14, 2016

12 Biggest Mid-Day Losers For Tuesday

Benzinga.com  September 13, 2016

Technical Roundup on Biotech Stocks -- Anavex Life Sciences, Threshold Pharma, StemCells, and Aratana Therapeutics

PR Newswire August 17, 2016

Anavex Reports Fiscal Third Quarter 2016 Financial Results

GlobeNewswire August 11, 2016

Anavex Confirms Phase 2a Trial Data Of ANAVEX 2-73 In Alzheimer's Patients Presented At AAIC

Benzinga.com  July 29, 2016

Anavex Confirms Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients Presented at AAIC 2016

GlobeNewswire July 29, 2016

Anavex Presents 31-Week Efficacy Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients at AAIC 2016

GlobeNewswire July 27, 2016

Anavex Presents 31-Week Safety Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients at AAIC 2016

GlobeNewswire July 24, 2016

Anavex to Present at the Alzheimer’s Association International Conference (AAIC) 2016

GlobeNewswire July 12, 2016

Anavex to Present at the 2016 Rett Syndrome Symposium

GlobeNewswire June 23, 2016

A Peek Into The Markets: U.S. Stock Futures Edge Higher Ahead Of Yellen Speech

Benzinga.com  June 22, 2016

Anavex Gets FDA Orphan Drug Status For ANAVEX 2-73 For Infantile Spasms Treatment

Benzinga.com  June 22, 2016

Anavex Announces U.S. FDA Orphan Drug Designation for ANAVEX 2-73 for Treatment of Infantile Spasms

GlobeNewswire June 22, 2016

Coverage of Biotechnology Equities - Pacific Biosciences of California, Peregrine Pharma, Dynavax Technologies and Anavex Life Sciences

PR Newswire June 10, 2016